Core Viewpoint - The company, Brain Dynamics Aurora-B (06681), has seen its stock price increase by over 5%, currently trading at 6.51 HKD with a transaction volume of 48.33 million HKD, following the announcement of its participation in a significant national technology project focused on the prevention and treatment of cognitive disorders related to intracranial atherosclerotic stenosis [1] Group 1: Project Involvement - The company’s wholly-owned subsidiary, Smart Genius Technology, is a key collaborator in the national major science and technology project titled "Research on the Prevention and Treatment of Cancer, Cardiovascular, Respiratory, and Metabolic Diseases" [1] - The project specifically addresses the challenges in diagnosing cognitive disorders caused by intracranial atherosclerotic stenosis (ICAS) and aims to establish a deep reasoning model and a comprehensive management system for early disease screening, risk assessment, and intervention tools [1] Group 2: Technological Development - As a core technology unit, the company will be responsible for the development of the deep reasoning model related to cognitive disorders caused by ICAS and the construction of a digital diagnosis and treatment platform [1] - The project has recently been officially launched, indicating a significant step forward in the company's technological capabilities and contributions to the healthcare sector [1] Group 3: Collaboration and Recognition - Smart Genius Technology, in collaboration with Xuanwu Hospital of Capital Medical University, has successfully applied for the establishment of the "Beijing Key Laboratory of Digital Medical for Cognitive Disorders," which has also been officially approved [1] - This collaboration highlights the company's commitment to advancing research and development in the field of cognitive health and its strategic partnerships with leading medical institutions [1]

Core Viewpoint - Brain动极光-B (06681) has seen a stock price increase of over 5%, currently trading at 6.51 HKD with a transaction volume of 48.33 million HKD, following the announcement of its participation in a significant national technology project focused on the treatment of cognitive disorders related to intracranial atherosclerotic stenosis [1] Group 1: Company Developments - Brain动极光's wholly-owned subsidiary, 智精灵科技, is a key collaborator in the national technology major project titled "Research on the Prevention and Treatment of Cancer, Cardiovascular, Respiratory, and Metabolic Diseases," specifically focusing on cognitive disorders related to intracranial atherosclerotic stenosis [1] - The project aims to establish key technologies for digital diagnosis and treatment of cognitive disorders, utilizing deep reasoning large models and a comprehensive management system for early disease screening, risk assessment, and intervention tools [1] - 智精灵科技 has also recently received approval for the establishment of the "Beijing Key Laboratory for Digital Medical Treatment of Cognitive Disorders," in collaboration with Capital Medical University Xuanwu Hospital [1] Group 2: Industry Context - The national technology major project addresses the clinical challenges of diagnosing and treating cognitive disorders caused by intracranial atherosclerotic stenosis (ICAS), indicating a growing focus on advanced digital health solutions in the medical field [1] - As a core technology provider, Brain动极光 is tasked with the development of deep reasoning models related to cognitive disorders and the construction of a digital diagnosis and treatment platform, highlighting the company's strategic positioning in the healthcare technology sector [1]

每经AI快讯，12月22日，港股脑动极光午后持续拉升，现涨超17%。 ...

（文章来源：第一财经） 脑动极光午后持续拉升涨超18%，消息面上，公司公告参与国家科技重大专项研究课题及获批认知障碍 数字医疗北京市重点实验室。 ...

来源：格隆汇APP 格隆汇12月22日丨脑动极光-B(6681.HK)午后持续拉升涨超19%报7.02港元；消息面上，公司公告参与国 家科技重大专项研究课题及获批认知障碍数字医疗北京市重点实验室。 ...

公告称，本次启动的国家科技重大专项，聚焦ICAS相关认知障碍的诊疗难题，依托多学科交叉优势开 展系统性研究，核心方向包括建立ICAS相关认知障碍的评估技术体系及深度推理预测大模型，以提供 疾病早期筛查、风险预判和预防、干预的诊疗工具，并建立ICAS相关认知障碍全场景闭环管理体系。 本文源自：智通财经网 本项目已于近期正式启动。同时，智精灵科技与首都医科大学宣武医院(宣武医院)等联合申报的"认知 障碍数字医疗北京市重点实验室"亦已于近日正式获批成立。 智通财经获悉，脑动极光-B(06681)涨超5%，截至发稿，涨5.09%，报6.18港元，成交额1666.49万港 元。 消息面上，12月22日，脑动极光-B发布公告，公司旗下全资附属公司北京智精灵科技有限公司(智精灵 科技)作为重要合作单位，共同参与国家科技重大专项"癌症、心脑血管、呼吸和代谢性疾病防治研 究"项目，课题名称为《基于深度推理大模型的颅内动脉粥样硬化狭窄相关认知障碍数字诊疗关键技术 建立及场景化应用》(国家科技重大专项)。 ...

Core Viewpoint - Brainstorm Aurora-B (06681) has seen a stock price increase of over 5%, currently trading at 6.18 HKD with a transaction volume of 16.66 million HKD, following the announcement of its participation in a significant national technology project focused on the prevention and treatment of various diseases, including cognitive disorders related to intracranial atherosclerosis [1] Group 1: Company Developments - The company announced that its wholly-owned subsidiary, Beijing Zhijingling Technology Co., Ltd. (Zhijingling Technology), is a key partner in the national technology major project titled "Research on the Prevention and Treatment of Cancer, Cardiovascular, Respiratory, and Metabolic Diseases" [1] - The project, which has recently been officially launched, aims to address diagnostic challenges related to cognitive disorders associated with intracranial atherosclerosis (ICAS) [1] - Zhijingling Technology, in collaboration with Xuanwu Hospital of Capital Medical University, has also successfully established the "Beijing Key Laboratory of Digital Medical for Cognitive Disorders" [1] Group 2: Project Focus and Objectives - The national technology major project focuses on the diagnostic challenges of ICAS-related cognitive disorders, leveraging interdisciplinary advantages for systematic research [1] - Key objectives include the establishment of an assessment technology system for ICAS-related cognitive disorders and the development of a deep reasoning predictive model to provide early screening, risk assessment, prevention, and intervention tools [1] - The project aims to create a comprehensive management system for ICAS-related cognitive disorders, ensuring a closed-loop management approach across various scenarios [1]

Core Viewpoint - Brain Dynamics Aurora-B (06681) has announced its participation in a significant national science and technology project focused on the prevention and treatment of diseases such as cancer, cardiovascular, respiratory, and metabolic diseases, specifically targeting cognitive disorders related to intracranial atherosclerosis [2][5]. Group 1 - The company's stock price increased by 6.62%, currently trading at 6.28 HKD with a transaction volume of 34.81 million HKD [2][5]. - The project, titled "Establishment of Key Technologies for Digital Diagnosis and Treatment of Cognitive Disorders Related to Intracranial Atherosclerosis," has officially commenced [2][5]. - The project aims to develop a comprehensive assessment technology system and deep reasoning predictive model for cognitive disorders associated with intracranial atherosclerosis, providing tools for early disease screening, risk assessment, prevention, and intervention [2][5]. Group 2 - The establishment of the "Beijing Key Laboratory for Digital Medical Treatment of Cognitive Disorders," in collaboration with Capital Medical University Xuanwu Hospital, has also been officially approved [2][5]. - The project leverages interdisciplinary advantages to conduct systematic research on the diagnostic challenges of cognitive disorders related to ICAS [2][5]. - The initiative will create a closed-loop management system for cognitive disorders associated with ICAS [2][5].

脑动极光-B(06681)发布公告，公司旗下全资附属公司北京智精灵科技有限公司(智精灵科技)作为重要合 作单位，共同参与国家科技重大专项"癌症、心脑血管、呼吸和代谢性疾病防治研究"项目，课题名称为 《基于深度推理大模型的颅内动脉粥样硬化狭窄相关认知障碍数字诊疗关键技术建立及场景化应用》 (项目编号：2025ZD0546200)(国家科技重大专项)。本项目已于近期正式启动。同时，智精灵科技与首 都医科大学宣武医院(宣武医院)等联合申报的"认知障碍数字医疗北京市重点实验室"亦已于近日正式获 批成立。 本次启动的国家科技重大专项，聚焦ICAS相关认知障碍的诊疗难题，依托多学科交叉优势开展系统性 研究，核心方向包括建立ICAS相关认知障碍的评估技术体系及深度推理预测大模型，以提供疾病早期 筛查、风险预判和预防、干预的诊疗工具，并建立ICAS相关认知障碍全场景闭环管理体系。 本项目的实施旨在建立国际领先的ICAS相关认知障碍诊疗技术体系，构建符合中国国情的疾病管理模 式，有效预防与延缓疾病进展，助力"健康中国"战略。本项目由宣武医院牵头，联合中国医学科学院北 京协和医院、中国科学院心理研究所、吉林大学、北京师範大学及智 ...

Core Viewpoint - The company, through its subsidiary Beijing Zhijingling Technology Co., Ltd., is participating in a national major science and technology project focused on the diagnosis and treatment of cognitive disorders related to intracranial atherosclerotic stenosis (ICAS) [1][2][3] Group 1: Project Overview - The national major science and technology project aims to address the diagnostic challenges of ICAS-related cognitive disorders by developing a comprehensive assessment technology system and deep reasoning predictive models [2] - The project is led by Xuanwu Hospital and involves collaboration with several prestigious institutions, including the Chinese Academy of Medical Sciences and Jilin University, bringing together top experts from neurology, cognitive neuroscience, psychology, and artificial intelligence [2][3] Group 2: Company Role and Contributions - The company will leverage its expertise in digital diagnosis and treatment of neurological and psychiatric disorders to develop deep reasoning models and digital treatment platforms for ICAS-related cognitive disorders [3] - The newly established Beijing Key Laboratory for Digital Therapy of Cognitive Disorders will integrate clinical medicine, basic research, technology development, and hardware innovation, with the company playing a key role in algorithm development and user experience optimization [3]